Chronic Myeloid Leukemia - PowerPoint PPT Presentation


PPT – Chronic Myeloid Leukemia PowerPoint presentation | free to download - id: 4d1e6-MGNjM


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation

Chronic Myeloid Leukemia


Disorder of the stem cells in bone marrow ... Confirmed with bone marrow biopsy and FISH and/or PCR that shows presence of ... Using bone marrow from a donor ... – PowerPoint PPT presentation

Number of Views:2183
Avg rating:3.0/5.0
Slides: 16
Provided by: kristin62
Learn more at:


Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Chronic Myeloid Leukemia

Chronic Myeloid Leukemia
  • Chronic Myelogenous Leukemia
  • Cancer of the granulocytes or monocytes, compared
    to leukocytes in lymphocytic leukemias
  • Comprises about 14 of all adult leukemias
  • Males slightly higher than females
  • One of the first cancers to have a specific
    genetic link to a chromosomal mutation identified
    for the disease
  • Philadelphia Chromosome

  • Disorder of the stem cells in bone marrow
  • General infection fighting cells are the most
    harmed gt granulocytes and monocytes (aka,
  • These immature cells take over the bodys mature
    neutrophils and hinder the bodys ability to
    fight infection properly
  • CML is caused by a genetic mutation with
    chromosomes 9 and 22 in the body
  • Abl on chromosome 9 is translocated to chromosome
    22 and fuses with Bcr
  • This ABL-BCR protein is an unregulated tyrosine
    kinase and thus, is the source of the
    reproduction of immature granulocytes
  • Other functions include upstream changes of DNA
    repair mechanisms, suppression of the bodys
    programmed cell death proteins, and changes in
    cytoskeletal structures

(No Transcript)
(No Transcript)
How you are diagnosed
  • Usually by accident!
  • ?
  • Routine WBC test shows elevated leukocytes
  • Confirmed with bone marrow biopsy and FISH and/or
    PCR that shows presence of Philadelphia
  • Presence of myeloid cells in peripheral blood
    determines staging of disease
  • S/SX lethargy, pallor, night sweats, weight
    loss, anorexia, fever, lymphadenopathy,

  • Three main stages, determined by percentage of
    blast cells in the blood
  • Chronic Phase
  • Patient usually diagnosed
  • Fewer than 10 of cells in blood and bone marrow
    are granulocytes
  • Prognosis (with imatinib) 5yr 70, 10yr
  • Accelerated Phase
  • 10-19 of cells are granulocytes
  • Blastic Phase, aka blast crisis
  • Fulminant symptoms of disease, multiple organ
  • 20-30 or more granulocytes in bone marrow and
  • Prognosis UNPROMISING, 2 months, may extend
    survival with newer drugs or chemotherapy

Treatment Options
  • Pharmacotherapy
  • Newer drugs are prolonging chronic phase and
    increasing the number of patients who enter into
  • They are easier on the body versus SCT
  • Old Standard hydroxyurea (no possible cytogenic
    response) or interferon alpha cytarabine
  • New Standard tyrosine kinase inhibitors
  • Imatinib, dasatanib, nilotonib
  • Stem Cell Transplant
  • Using bone marrow from a donor to resupply the
  • Can be the only curative measure, although many
  • Must be good candidates for surgery
  • Must have a relatively short time from diagnosis
    to transplant
  • Matching donor
  • Possible relapse of CML
  • Rejection (GVHD)

How to measure treatment
  • Hematologic response
  • The response that reflects a decrease in white
    blood cell count and platelets
  • A hematological response in CML would be shown
    when a patient went from about a 10 granulocyte
    count to a 4 granulocyte count
  • Good prognostic sign
  • Cytogenic response
  • Reduction or elimination of Ph cells in bone
  • Can be Complete, Major or Minor
  • 0, 1-34, 35-90 respectively in bone marrow
  • Done by FISH and/or PCR
  • Chronic phase patients who have cytogenic
    responses have a significant increase in survival
    and a deterrence to progression to accelerated or
    blast phases
  • Better prognostic sign

New Treatments Tyrosine Kinase Inhibitors
  • Enzyme that is able to transfer a phosphate group
    from ATP to a tyrosine residue in a protein
  • Main proponents of signal transduction of enzymes
    in body, in bone marrow, this is one of many
    proteins that plays a large role in hematopoeisis
  • In CML, the BRC-ABL gene is a tyrosine kinase
    that is constituently active, and thus produces
    unregulated granulocytes
  • A great advance in the treatment of CML was to
    develop a tyrosine kinase inhibitor, that turns
    off the active TK in the body, specific to the
    mutated gene, BRC-ABL
  • The first generation TK inhibitor for CML is
    imatinib mesylate

Imatinib mesylate
  • First generation TK inhibitor
  • Dosed in 400mg and 800mg tablets
  • Binds the closed form of the ATP binding site in
  • IRIS study 97 pts in hematological remission
    and major cytogenic remission was 87 compared to
    interferon alpha cytarabine after 19 months
  • IRIS Follow-up five year study if patient shows
    a 3-log molecular response to imatanib, then
    probability of progression-free survival at 4
    years is 98 (Frame 2006)
  • Side Effects Fluid retention (76), diarrhea
    (30-60), nausea (43-73), fatigue, muscle
    cramps, bone pain, rash, neutropenia,
    thrombocytopenia (although might be signs of
  • Most can be alleviated with common medications
    and are not a cause of discontinuation
  • Resistance occurs

  • A small number of patients show some resistance
    to Imatanib
  • The BRC-ABL transcript has the ability to mutate
    and thus make imatinib ineffective
  • Imatinib binds to the closed conformation and
    BRC-ABL can mutate to the open conformation and
    thus makes imatanib ineffective
  • Two 2nd generation TKIs have proven to be more
    potent and are in trials to determine
    effectiveness against resistance to imatanib

2nd Generation TKIs
  • Dasatanib
  • aka Sprycel 300 times more potent than imatanib
  • Binds to multiple conformational states (open and
    closed), unlike imatanib
  • Very new drug, approved in July, 2006 for further
    clinical trials
  • Side Effects myelosuppression which can lead to
    bleeding, infection and fatigue, fluid retention,
    headache, skin rash, nausea
  • Can be used in patients who are resistant to
  • Nilotonib
  • Structurally similar to imatanib
  • 20 to 50 times more potent than imatanib
  • Binds in the closed conformation
  • Not FDA approved, still under scrutiny
  • COMBOS with dasatanib, nilotonib and imatinib
    have proven that they do not inhibit each other,
    and prove useful in pilot experiments with
    resistant cell clones

Treatment Algorithm
  • Faderl S, Kantarjian HM. Chronic Myelogenous
    Leukemia and Other Myeloproliferative Disorders.
    BOOK, check citing!. ACP Medicine. 2006.
    vol 2(2570-79)
  • Fausel C. Novel treatment strategies for chronic
    myeloid leukemia. Am J Health-Syst Pharm. 2006
    Dec 1 63(Suppl 8) S15-S20.
  • Grigg A, Hughes T. Role of Allogenic Stem Cell
    Transplantation for Chronic Myeloid Leukemia in
    the Imatinib Era. Biol Blood Marrow Transplant.
    2006 Mar 29 12795-807.
  • http//
  • http//
  • http//
  • http//
  • http//